The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy

2017 ◽  
Vol 19 (11) ◽  
pp. 980-986 ◽  
Author(s):  
D. L. H. Baird ◽  
Q. Denost ◽  
C. Simillis ◽  
G. Pellino ◽  
S. Rasheed ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Neoadjuvant Chemoradiotherapy ◽  
Cancer Surgery ◽  
Rectal Cancer Surgery ◽  
Node Negative

Is Adjuvant Chemotherapy Really Needed After Curative Surgery for Rectal Cancer Patients Who are Node-Negative After Neoadjuvant Chemoradiotherapy?

2011 ◽  
Vol 19 (4) ◽  
pp. 1206-1212 ◽  
Author(s):  
Ravi P. Kiran ◽  
Hasan T. Kirat ◽  
Adele N. Burgess ◽  
Pasha J. Nisar ◽  
Matthew F. Kalady ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Neoadjuvant Chemoradiotherapy ◽  
Curative Surgery ◽  
Node Negative

scholarly journals Drug-Induced Interstitial Pneumonia due to Application of FOLFOX as Adjuvant Chemotherapy after Rectal Cancer Surgery: A Case Report and Literature Review

2020 ◽  
Vol 13 (2) ◽  
pp. 768-773 ◽  
Author(s):  
Senichiro Yanagawa ◽  
Nozomi Karakuchi ◽  
Tetsuya Mochizuki ◽  
Shinya Kodama ◽  
Yukio Takeshima ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Interstitial Pneumonia ◽  
Steroid Therapy ◽  
Disease Free Survival ◽  
Cancer Surgery ◽  
Rectal Cancer Surgery ◽  
High Dose ◽  
Drug Induced ◽  
Steroid Pulse

The regimen of oxaliplatin with 5-fluorouracil plus l-leucovorin (FOLFOX) has become one of the most commonly used first-line chemotherapy for patients with advanced colorectal cancer and it provides an increase in disease-free survival as well as an overall survival benefit. Although FOLFOX chemotherapy has helped to improve the clinical outcomes in these patients, the regimen is associated with some therapeutic issues or uncontrolled side effects. Gastrointestinal, neurosensory, and hematological toxicities have frequently been observed in patients treated with FOLFOX, and consequently, some palliative treatment has been established to combat such complications. However, pulmonary toxicities including drug-induced interstitial pneumonia (DI-IP) is rarely observed in these patients and a curative treatment is yet to be established. DI-IP due to chemotherapy is most commonly observed in patients treated with mitomycin, paclitaxel, docetaxel, or gemcitabine. Steroid therapy is mostly used to treat DI-IP, although the efficacy of such treatments is not supported with adequate evidence. FOLFOX-induced interstitial pneumonia (FIIP) is rarely observed, and several case reports of FIIP treated with steroids have been published previously that showed the mortality is extremely high. Here, we present a 74-year-old woman who received modified FOLFOX6 as adjuvant chemotherapy after rectal cancer surgery. The patient experienced FIIP, which improved after application of steroid pulse (high-dose methylprednisolone at 1,000 mg/day for 3 days) and tapering (starting with prednisolone at 40 mg/day) therapy. Our data suggest that such a steroid therapy could represent an effective treatment option for FIIP.

scholarly journals Prospective, randomised, multicentre, open-label trial, designed to evaluate the best timing of closure of the temporary ileostomy (early versus late) in patients who underwent rectal cancer resection and with indication for adjuvant chemotherapy: the STOMAD (STOMa closure before or after ADjuvant therapy) randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e044692
Author(s):  
Paolo Massucco ◽  
Andrea Fontana ◽  
Michela Mineccia ◽  
Serena Perotti ◽  
Giovannino Ciccone ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Adjuvant Therapy ◽  
Health System ◽  
Cancer Surgery ◽  
Rectal Cancer Surgery ◽  
Stoma Closure ◽  
System Perspective ◽  
Patient Reported ◽  
Temporary Ileostomy

IntroductionTemporary ileostomy is a valuable aid in reducing the severity of complications related to rectal cancer surgery. However, it is still unclear what is the best timing of its closure in relation to the feasibility of an adjuvant treatment, especially considering patient-reported outcomes and health system costs. The aim of the study is to compare the results of an early versus late closure strategy in patients with indication to adjuvant chemotherapy after resection for rectal cancer.Methods and analysisThis is a prospective multicentre randomised trial, sponsored by Rete Oncologica Piemonte e Valle d’Aosta (Oncology Network of Piedmont and Aosta Valley-Italy). Patients undergone to rectal cancer surgery with temporary ileostomy, aged >18 years, without evidence of anastomotic leak and with indication to adjuvant chemotherapy will be enrolled in 28 Network centres. An early closure strategy (between 30 and 40 days from rectal surgery) will be compared with a late one (after the end of adjuvant therapy). Primary endpoint will be the compliance to adjuvant chemotherapy with and without ileostomy. Complications associated with stoma closure as well as quality of life, costs and oncological outcomes will be assessed as secondary endpoints.Ethics and disseminationThe trial will engage the Network professional teams in a common effort to improve the treatment of rectal cancer by ensuring the best results in relation to the most correct use of resources. It will take into consideration both the patients’ point of view (patient-reported outcome) and the health system perspective (costs analysis). The study has been approved by the Ethical Review Board of Città della Salute e della Scienza Hospital in Turin (Italy). The results of the study will be disseminated by the Network website, medical conferences and peer-reviewed scientific journals.Trial registration numberNCT04372992.

scholarly journals Clinical Outcomes of Ileostomy Closure According to Timing During Adjuvant Chemotherapy After Rectal Cancer Surgery

2019 ◽  
Vol 35 (4) ◽  
pp. 187-193 ◽  
Author(s):  
Yoo Jin Choi ◽  
Jung-Myun Kwak ◽  
Neul Ha ◽  
Tae Hoon Lee ◽  
Se Jin Baek ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Clinical Outcomes ◽  
Cancer Surgery ◽  
Ileostomy Closure ◽  
Rectal Cancer Surgery

scholarly journals The effects of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer surgery patients

2014 ◽  
Vol 40 (11) ◽  
pp. 1421-1428 ◽  
Author(s):  
M.A. West ◽  
L. Loughney ◽  
C.P. Barben ◽  
R. Sripadam ◽  
G.J. Kemp ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Physical Fitness ◽  
Neoadjuvant Chemoradiotherapy ◽  
Cancer Surgery ◽  
Rectal Cancer Surgery

Impact of Specialisation in the Practice of Rectal Cancer Surgery at a District General Hospital

Endoscopy ◽  
2004 ◽  
Vol 36 (10) ◽  
Author(s):  
AL Gidwani ◽  
RS Date ◽  
D Hughes ◽  
P Neilly ◽  
R Gilliland
Keyword(s):  
Rectal Cancer ◽  
General Hospital ◽  
District General Hospital ◽  
Cancer Surgery ◽  
Rectal Cancer Surgery
Sign in / Sign up

Export Citation Format

Share Document